Key terms
About BEAM
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BEAM news
May 10
9:50pm ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Beam Therapeutics (BEAM), Cormedix (CRMD) and Applied Therapeutics (APLT)
May 10
1:18am ET
Beam Therapeutics: A Hold Rating Amid Controlled R&D Spending and Upcoming Clinical Milestones
May 09
8:30am ET
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
May 08
5:30am ET
Beam Therapeutics price target lowered to $33 from $42 at Barclays
May 07
9:11pm ET
Analysts’ Top Healthcare Picks: IDEAYA Biosciences (IDYA), Surgery Partners (SGRY)
May 07
1:30pm ET
Analysts’ Top Healthcare Picks: Esperion (ESPR), Beam Therapeutics (BEAM)
May 07
1:20pm ET
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Beam Therapeutics (BEAM)
Apr 26
11:02am ET
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
Apr 23
7:16am ET
Beam Therapeutics: A Strong Buy on Gene Editing Advancements and Strategic Growth Potential
Apr 22
4:37pm ET
Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing
Apr 02
7:25pm ET
Beam Therapeutics: A Buy Rating Amidst Gene Editing Industry Developments
Apr 02
7:14pm ET
Citi sees limited readthrough for Beam Therapeutics from VERVE-101 trial pause
Apr 02
3:20pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 30
3:48pm ET
Is Beam Therapeutics Stock (NASDAQ:BEAM) Too Late to the Game?
Mar 28
6:12am ET
Korro Bio price target raised to $115 from $100 at H.C. Wainwright
Mar 26
1:25pm ET
Beam Therapeutics: A Strong Buy on Regulatory Clearance and Promising BEAM-302 Preclinical Data
Mar 26
6:20am ET
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Beam Therapeutics (BEAM) and Glaukos (GKOS)
Mar 01
1:08am ET
Beam Therapeutics: Financial and Clinical Prospects Inform Hold Rating
Feb 28
7:50am ET
Beam Therapeutics price target raised to $35 from $27 at RBC Capital
Feb 28
6:32am ET
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
Feb 28
6:13am ET
Beam Therapeutics files automatic mixed securities shelf
Feb 28
6:00am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
Feb 28
5:40am ET
Beam Therapeutics: Strong Buy Rating on Impressive Q4 Earnings and Promising Pipeline Developments
Feb 28
5:23am ET
Beam Therapeutics price target raised to $42 from $26 at Barclays
Feb 28
3:36am ET
Barclays Reaffirms Their Hold Rating on Beam Therapeutics (BEAM)
Feb 27
1:56pm ET
William Blair Keeps Their Buy Rating on Beam Therapeutics (BEAM)
Feb 27
6:33am ET
Beam Therapeutics reports Q4 EPS $1.73, consensus ($1.01)
No recent press releases are available for BEAM
BEAM Financials
Key terms
Ad Feedback
BEAM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BEAM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range